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Abstract: To analyze the clinical profile and therapeutic strategy in atrial fibrillation (AF) according
to gender in a contemporaneous patient cohort a prospective, multicenter observational study was
performed on consecutive patients diagnosed with AF and assessed by cardiology units in the region
of Galicia (Spain). A total of 1007 patients were included, of which 32.3% were women. The mean
age of the women was significantly greater than that of the men (71.6 versus 65.7 years; p < 0.001),
with a higher prevalence of hypertension (HTN) and valve disease. Women more often reported
symptoms related to arrhythmia (28.2% in EHRA class I versus 36.4% in men), with a poorer level of
symptoms (EHRA classes IIb and III). Thromboembolic risk was significantly higher among women
(CHA2DS2-VASc 3 ± 1.3 versus 2 ± 1.5), in the same way as bleeding risk (HAS-BLED 0.83 ± 0.78
versus 0.64 ± 0.78) (p < 0.001), and women more often received anticoagulation therapy (94.1%
versus 87.6%; p = 0.001). Rhythm control strategies proved significantly less frequent in women
(55.8% versus 66.6%; p = 0.001), with a lesser electrical cardioversion (ECV) rate (18.4% versus 27.3%;
p = 0.002). Perceived health status was poorer in women. Women were older and presented greater
comorbidity than men, with a greater thromboembolic and bleeding risk. Likewise, rhythm control
strategies were less frequent than in men, despite the fact that women had poorer perceived quality
of life and were more symptomatic.
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1. Introduction
Atrial fibrillation (AF) is the most common sustained heart arrhythmia in the general
population [1,2], with a current prevalence of 2–4% [1,3–5] that is expected to more than
double in the coming years due to the prolongation of life expectancy and the development
of new detection methods [6].
There is evidence of gender-related differences in relation to AF, though women are
under-represented in the existing studies [2]. In this respect, it has been reported that the
age-adjusted incidence, prevalence and risk of suffering AF during life are lower in women
than in men [2]. Furthermore, women are older at the time of detection of the arrhythmia,
and the risk factor and comorbidity profiles differ with respect to men, in the same way as
the symptoms burden [2]. Women present a higher CHA2DS2-VASc score, and stroke among
females tends to be more severe and disabling [7]. However, there are data suggesting that
women present poorer control of anticoagulation with warfarin than men, with a greater
residual risk despite correct control with vitamin K antagonists (VKAs] [7]. The efficacy
of direct-acting oral anticoagulants (DOACs) does not appear to vary according to gender,
though here again women are under-represented in the pivotal studies [7].
The clinical management strategy also differs between men and women. The available
data indicate more frequent prescription of rate control strategies in women [2]. On the
other hand, the use of antiarrhythmic drugs (AADs) in women is associated to a greater
incidence of prolonged QT-interval arrhythmic events with class IA and III drugs, and of
sinus node dysfunction requiring pacemaker implantation [7].
The REgistro GallEgo Intercéntrico de Fibrilación Auricular (REGUEIFA) trial is a
prospective, multicenter observational registry of consecutive patients diagnosed with
AF [8]. The present study was carried out to analyze and compare the clinical characteristics
of patients with AF and the therapeutic strategies used according to gender in the cohort
of the REGUEIFA trial.
2. Material and Methods
The study design and methods have been previously described [8]. A total of 1007 pa-
tients were recruited between 2 January 2018 and 27 February 2020, belonging to the cohort
of the REGUEIFA trial [8].
2.1. Inclusion Criteria
− Men and women aged ≥ 18 years.
− An electrocardiographic or external or implantable Holter monitoring diagnosis of AF
with a duration of over 30 s.
− A registered AF episode in the last year.
− Possible sinus rhythm at the time of inclusion.
2.2. Exclusion Criteria
− Patients in which long-term follow-up is not contemplated or not possible.
− Patients with secondary transient AF due to reversible causes.
− Patients enrolled in interventional studies conditioning treatments, frequency of consul-
tation or diagnostic procedures.
2.3. Ethical Statement
The study protocol was performed according to the principles of the Helsinki Declara-
tion and the Clinical Research Ethics Committee (CREC) of Galicia (Spain) approved the
study, with reference code 2016/376.
2.4. Participating Hospitals
A total of eight hospitals of the Galician Health Department (Servicio Gallego de
Salud (SERGAS)) participated in the study, covering 100% of the population in the region
of Galicia (Spain).
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2.4.1. Conduct of the Study
All the patients meeting the inclusion criteria and none of the exclusion criteria were
considered for enrollment in the study, and the corresponding data were entered in the
electronic case report form (eCRF). The collected information was sent to the registry coor-
dinating center through secure websites, with due observation of data confidentiality. All
patients received the patient information sheet, and written informed consent was obtained
in accordance with the local requirements before any of the study-related procedures were
carried out (i.e., data transfer from the case histories to the eCRF). All patient-related
information complied with Act 3/2018, of 5 December, referred to personal data protection,
and with Act 41/2002, regulating patient autonomy and rights and obligations in relation
to clinical documentation and information. All consenting patients were assigned a specific
number code serving as personal identifier.
2.4.2. Data Registry
The study data were collected on occasion of the baseline visit. The data referred to
the international normalized ratio (INR) of those patients receiving treatment with VKAs
were also recorded. The information was entered in the eCRF designed by the principal
investigators and produced by the company Odds S.L. (Odds S.L., A Coruña, Spain)
2.4.3. Quality Assurance and Control
The study supervisor checked 10% of all the eCRF against the source documentation
in the study centers, in accordance with the supervision protocol.
2.5. Statistical Analysis
Quantitative and qualitative variables were reported as the mean ± standard deviation
(SD) and percentages, respectively. The differences between the two groups (men versus
women) were analyzed using the chi-square test or Fisher exact test in the case of qualitative
variables, and the Mann-Whitney U-test (two-sample Wilcoxon rank-sum test) in the case
of quantitative variables. The Kruskal-Wallis test was used to compare the INR levels in
the last 6 months and the time in therapeutic range (TTR) between men and women.
Statistical significance was considered for p = 0.05.
3. Results
3.1. Basal Characteristics
Cardiovascular Risk Factors (CVRFs)
Thirty-two percent of the patients included in the study were women. The mean age of
the global sample was 67.6 years, and HTN was the most prevalent CVRF (62%). Compared
with the men, the females in our study were significantly older (71.6 versus 65.7 years on
average; p < 0.001) and were more often hypertensive (p = 0.05). No gender differences were
observed in relation to other risk factors such as obesity, diabetes mellitus or dyslipidemia.
Toxic habits (smoking and alcohol) were more common in men (p < 0.001) (Table 1).
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Table 1. Basal characteristics.
Variables Women RhC Men RhC Women RC Men RC p-Value
Age n 182 454 144 227 <0.001
mean ± SD 67.94 ± 8.96 60.98 ± 10.91 76.44 ± 8.57 75.22 ± 9.68
Body mass index n 181 452 144 227 0.955
mean ± SD 29.92 ± 5.27 29.73 ± 4.74 29.18 ± 5.83 29.44 ± 4.79
Diameter of LA (mm)
n 87 233 80 124 0.002
mean ± SD 42.07 ± 8.92 44.86 ± 10.8 43.44 ± 12.77 43.93 ± 14.07
Volume of LA (ml/m2)
n 33 87 30 55 0.054
mean ± SD 42.51 ± 19.96 55.3 ± 34.86 65.98 ± 38.42 62.47 ± 30.44
LVEF (%)
n 117 281 102 167 0.002
mean ± SD 59.32 ± 10.71 55.26 ± 12.4 58.75 ± 11.19 53.5 ± 14.64
HF based on NYHA functional class (n) 17 64 29 40 0.009
I 0.00% 28.13% 17.24% 10.00%
II 58.82% 54.69% 58.62% 50.00%
III 41.18% 17.19% 20.69% 40.00%
IV 0.00% 0.00% 3.45% 0.00%
CHA2DS2-VASc scale
n 182 454 144 227 <0.001
mean ± SD 2.62 ± 1.32 1.52 ± 1.32 3.64 ± 1.22 3 ± 1.35
HTN
n 182 454 144 227 0.101
% 61.54 54.41 72.92 71.81
COPD
n 182 454 144 227 0.058
% 3.85 8.15 9.72 22.03
Paroxysmal AF n 182 454 144 227 0.009
% 39.01 28.41 7.64 5.29
EHRA classification (n) 182 454 144 227 0.027
I 22.53% 33.70% 35.42% 41.85%
II a 46.70% 42.07% 32.64% 30.40%
II b 20.33% 16.52% 18.75% 14.98%
III 10.44% 6.83% 12.50% 11.89%
IV 0.00% 0.88% 0.69% 0.88%
AF: atrial fibrillation; COPD: chronic obstructive pulmonary disease; EHRA: European heart rhythm association; HTN: hypertension; LA: left
atrium; NYHA: New York Heart Association; RhC: rhythm control; RC: rate control; HF: heart failure; LVEF: left ventricular ejection fraction.
3.2. Complementary Tests
Creatinine concentration was significantly lower in women (p < 0.01). In turn, the left
ventricular ejection fraction (LVEF) was average 4% higher than in men (p < 0.01). The diameter
of the left atrium was significantly smaller in women, though not so the atrial volume.
Nine percent of the patients presented bundle block, with a significant two-fold higher
prevalence in men versus women (10% versus 5%; p < 0.01). Right bundle block was the
most frequent presentation. Both left and right bundle block were more prevalent in men,
though statistical significance was not reached (p = 0.19 and p = 0.06 for left and right
bundle block, respectively) (Table 2).
Table 2. Complementary tests.
Variables All Men Women p-Value
Complementary tests
Creatinine (mg/dL) 956 0.99 ± 0.36 646 1.04 ± 0.35 310 0.88 ± 0.34 <0.001
LVEF (%) 667 56.06 ± 12.73 448 54.6 ± 13.29 219 59.05 ± 10.91 <0.001
Diameter of LA (mm) 524 43.96 ± 11.7 357 44.54 ± 12.02 167 42.73 ± 10.92 0.011
Volume of LA (mL/m2) 205 56.73 ± 32.94 142 58.07 ± 33.29 63 53.68 ± 32.18 0.212
Bundle block 90 8.94% 71 10.43% 19 5.83% 0.017
LBB 38/90 42.22% 27/71 38.03% 11/19 57.89% 0.190
RBB 51/90 56.67% 44/71 61.97% 7/19 36.84% 0.068
LVEF: left ventricular ejection fraction; LA: left atrium; LBB: left bundle block; RBB: right bundle block.
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3.3. Cardiovascular History
Approximately 15% of the patients had a history of heart failure (HF). There were no
gender differences in the prevalence of HF or in NYHA functional class. Coronary disease
was almost twice as frequent in men versus women—the difference being statistically
significant (13.3% versus 7.6%; p = 0.008). A history of myocardiopathy was likewise
approximately two times more common in men (9.4% versus 4.2%; p = 0.005). In contrast,
valve disease was more frequent in women (14.7% versus 10.1%; p = 0.03). In turn, almost
10% of the patients carried a pacemaker or implantable cardioverter defibrillator (ICD),
with no differences between men and women. Pacemakers were the most frequent devices
in both genders. On the other hand, women reprsented only three of the total of 24 ICDs in
the global study sample (Table 3).
Table 3. Cardiovascular history.
Variables All Men Women p-Value
Cardiovascular history
Type of device 100 72 28 0.068
Pacemaker carrier 76 76.00% 51 70.83% 25 89.29
ICD carrier 24 24.00% 21 29.17% 3 10.71
Heart failure 150 14.90% 104 15.27% 46 14.11 0.628
HF based on NYHA functional class 150 104 46 0.213
I 27 18.00% 22 21.15% 5 10.87%
II 82 54.67% 55 52.88% 27 58.70%
III 40 26.67% 27 25.96% 13 28.26%
IV 1 0.67% 0 0.00% 1 2.17%
NYHA functional class ≥ II 123/150 82.00% 82/104 78.85% 41/46 89.13% 0.168
Coronary disease (ischemic heart disease) 116 11.52% 91 13.36% 25 7.67% 0.008
Valve disease 117 11.62% 69 10.13% 48 14.72% 0.033
Cardiomyopathy 78 7.75% 64 9.40% 14 4.29% 0.005
ICD: implantable cardioverter defibrillator; HF: heart failure. NYHA: New York Heart Association.
3.4. Personal History, Comorbidities and Previous Thromboembolic Events and Bleeding Episodes
The prevalence of chronic obstructive pulmonary disease (COPD) was 50% lower in
women than in men (6.4% versus 12.7%; p = 0.002), while hypothyroidism was almost
four times more frequent in women (11.9% versus 3.9%; p < 0.001). There were no gender
differences in terms of the presence of hyperthyroidism or neoplastic disease. Six percent
of the patients had suffered thromboembolic events, with stroke representing almost half
of the total (2.8%). In turn, 3.5% of the study population had a history of bleeding, with no
differences between men and women (Table 4).
Table 4. Concomitant diseases.
Variables All Men Women p-Value
Personal history-concomitant diseases
COPD 108 10.72% 87 12.78% 21 6.44% 0.002
Neoplasms 83 8.24% 56 8.22% 27 8.28% 0.975
Hyperthyroidism 19 1.89% 15 2.20% 4 1.23% 0.334
Hypothyroidism 66 6.55% 27 3.96% 39 11.96% <0.001
Previous thromboembolic and bleeding events
Thromboembolic events 61 6.06% 42 6.17% 19 5.83% 0.833
Ischemic stroke 29 2.88% 19 2.79% 10 3.07% 0.805
Bleeding events 36 3.57% 23 3.38% 13 3.99% 0.625
COPD: chronic obstructive pulmonary disease.
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3.5. Risk Scales
The mean CHA2DS2-VASc risk score was 3 in women and 2 in men (p < 0.001). The
mean HAS-BLED bleeding risk score was also slightly higher in women (0.8 versus 0.6;
p < 0.001) (Table 5).
Table 5. Thromboembolic and bleeding risk scores.
Variables All Men Women p-Value
Thromboembolic/bleeding risk
CHA2DS2-VASc scale 1007 2.35 ± 1.54 681 2.01 ± 1.5 326 3.07 ± 1.37 <0.001
HAS-BLED scale 1007 0.7 ± 0.78 681 0.64 ± 0.78 326 0.83 ± 0.78 <0.001
3.6. Characteristics of Atrial Fibrillation
Most patients (38.9%) presented level IIa of the EHRA symptoms classification. The
percentage of asymptomatic individuals (level I of the EHRA classification) was higher in
the male group (36.4% versus 28.2%), while women more often presented class II and class
III (19.6% versus 16% and 11.3% versus 8.5%, respectively) (Table 6).
Statistically significant differences were also observed in terms of the clinical type
of AF (p = 0.009). In this regard, a distinction was made between first diagnosis AF and
paroxysmal, persistent, long duration persistent and permanent AF. Persistent AF was
the most frequent presentation both globally (26.3%) and in men (29.3%). In contrast,
permanent AF was the most common presentation in women (29.7%). There were no
significant gender differences in relation to paroxysmal AF (p = 0.1) (Table 6).
Table 6. Characteristics of previous atrial fibrillation management strategies.
Variables All Men Women p-Value
Characteristics of atrial fibrillation
EHRA classification 0.052
I 340 33.76% 248 36.42% 92 28.22%
IIa 392 38.93% 260 38.18% 132 40.49%
IIb 173 17.18% 109 16.01% 64 19.63%
III 95 9.43% 58 8.52% 37 11.35%
IV 7 0.70% 6 0.88% 1 0.31%
Clinical type of AF 0.009
First diagnosis 231 22.94% 160 23.49 71 21.78%
Paroxysmal 223 22.14% 141 20.70 82 25.15%
Persistent 265 26.32% 200 29.37% 65 19.94%
Long duration persistent 26 2.58% 15 2.20% 11 3.37%
Permanent 262 26.02% 165 24.23% 97 29.75%
Previous strategy
(if not first diagnosis of AF)
Rhythm control 403/627 64.27% 274/407 67.32% 129/220 58.64% 0.030
Electrical cardioversion 403 274 129 0.171
No 176 43.67% 112 40.88% 64 49.61%
1 143 35.48% 99 36.13% 44 34.11%
>1 84 20.84% 63 22.99% 21 16.28%
Electrical cardioversion
(yes/no) 227/403 56.33% 162/274 59.12% 65/129 50.39% 0.099
Ablation of AF 403 274 129 0.089
No 324 80.40% 215 78.47% 109 84.5%
Isolation of pulmonary
veins 76 18.86% 58 21.17% 18 13.95%
AV node ablation 3 0.74% 1 0.36% 2 1.55%
AF: atril fibrillation; AV: atrioventricular; EHRA: European heart rhythm association.
J. Clin. Med. 2021, 10, 3846 7 of 14
3.7. Previous Treatment Strategy (in Non-First Diagnosis of AF)
Previous rhythm control had been decided in 58.6% of the women and in 67.3% of the
men (p = 0.03). Electrical cardioversion had been performed in 59% of the men and in 50%
of the women (p = 0.09). Twenty-one percent of the men had undergone pulmonary vein
ablation versus 13.9% of the women (p = 0.08). In turn, atrioventricular node ablation had
been performed in three patients, of which two were women (Table 6).
3.8. Current Treatment Strategy
Rhythm control strategies were being applied in 66.6% of the men and in 55.8% of the
women—the difference being statistically significant (p = 0.001). Electrical cardioversion was
more often performed in men (27.3% versus 18.4%; p = 0.002). There were no gender differ-
ences in AF catheter ablation (16.8% versus 16.2%; p = 0.8). On the other hand, atrioventricular
node ablation remained more frequent in women (2% versus 0.2%; p = 0.007) (Table 7).
Antiarrhythmic drugs were prescribed in 42.2% of the men and in 31.2% of the women
(p = 0.001). Amiodarone, followed by flecainide, were the most frequently used AADs. The
distribution of the use of the five drugs contemplated in the study was similar in both groups.
No gender differences were observed in terms of the use of β-blockers, calcium antago-
nists or dihydropyridinic agents, digoxin, angiotensin II converting enzyme inhibitors (ACEIs)
or angiotensin II receptor antagonists (ARAs), statins or antiplatelet drugs, or as regards the
administration of dual therapy (antiplatelet medication and anticoagulation). In contrast,
diuretics were more often used by women (40.4% versus 31.4%; p = 0.005) (Table 8).
On comparing the basal characteristics of the women and men offered rhythm control,
the former was seen to be older (67.9 versus 60.9 years; p < 0.001), with a smaller left atrium
(diameter 42 mm versus 44.8 mm, p = 0.002; volume 42.5 mL/m2 versus 55.3 mL/m2,
p = 0.054), and a significantly greater LVEF (59.3% versus 55.2%; p = 0.002). Women also
presented paroxysmal AF more often (39% versus 28.4%; p = 0.009), with more severe
symptoms according to the EHRA classification (p = 0.027). Likewise, women presented
a higher CHA2DS2-VASc score (2.3 versus 1.5; p < 0.001), were more often hypertensive
(p = 0.1), and had a lesser incidence of COPD (3.8% versus 8.1%; p = 0.058) (Table 9).
Table 7. Current clinical management strategies.
Variables All Men Women p-Value
Current treatment of atrial fibrillation
Rhythm control strategy 636 63.16% 454 66.67% 182 55.83% 0.001
Catheter ablation 168 16.68% 115 16.89% 53 16.26% 0.802
Number of interventions 168 1.14 ± 0.38 115 1.15 ± 0.38 53 1.11 ± 0.38 0.435
Electrical cardioversion 246 24.43% 186 27.31% 60 18.4% 0.002
Number of interventions 246 1.32 ± 0.76 186 1.36 ± 0.83 60 1.18 ± 0.47 0.227
Implantation of devices 38 3.77% 22 3.23% 16 4.91% 0.191
Rate control interventions AV
node ablation 9 0.89% 2 0.29% 7 2.15% 0.007
AV: atrioventricular.
Table 8. Pharmacological treatment.
Variables All Men Women p-Value
Medication
Antiarrhythmic treatment 390 38.73% 288 42.29% 102 31.29% 0.001
Group I and/or III
antiarrhythmic drugs 389/390 99.74% 287/288 99.65% 102/102 100.00% 1.000
Type of group I and/or III
antiarrhythmic drugs 389 287 102 0.321
Amiodarone 182 46.79% 129 44.95% 53 51.96%
Dronedarone 6 1.54% 3 1.05% 3 2.94%
Sotalol 13 3.34% 9 3.14% 4 3.92%
Flecainide 183 47.04% 142 49.48% 41 40.20%
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Table 8. Conts.
Variables All Men Women p-Value
Propafenone 5 1.29% 4 1.39% 1 0.98%
Beta-blockers 689 68.42% 464 68.14% 225 69.02% 0.778
Non-dihydropyridinic
calcium antagonists 54 5.36% 37 5.43% 17 5.21% 0.886
Digoxin 62 6.16% 37 5.43% 25 7.67% 0.167
ACEIs/ARAs 517 51.34% 350 51.40% 167 51.23% 0.960
Diuretics 346 34.36% 214 31.42% 132 40.49% 0.005
Statins 466 46.28% 317 46.55% 149 45.71% 0.802
Antiplatelet medication 43 4.27% 33 4.85% 10 3.07% 0.192
Anticoagulation +
antiplatelet drugs 27 2.68% 21 3.08% 6 1.84% 0.302
Anticoagulation 904 89.77% 597 87.67% 307 94.17% 0.001
Type of anticoagulant 904 597 307 0.020
Vitamin K antagonist 532 58.85% 335 56.11% 197 64.17%
DOACs 372 41.15% 262 43.89% 110 35.83%
Type of DOAC 372 262 110 0.249
Dabigatran 128 34.41% 91 34.73% 37 33.64%
Edoxaban 50 13.44% 35 13.36% 15 13.64%
Rivaroxaban 105 28.23% 80 30.53% 25 22.73%
Apixaban 89 23.92% 56 21.37% 33 30.00%
ACEIs: angiotensin II converting enzyme inhibitors; ARAs: angiotensin II receptor antagonists; DOACS: direct-acting oral anticoagulants.
390 patients under Antiarrhythmic treatment (in bold).
Table 9. Basal characteristics of women and men subjected to rhythm control (RhC) versus rate control (RC).
Variables
All Men Women p-Value
n n n
Patients 1007 681 67.63 326 32.37
Age 1007 67.66 ± 11.98 681 65.73 ± 12.47 326 71.69 ± 9.74 <0.001
Body Mass Index (BMI) 1004 29.62 ± 5.02 679 29.63 ± 4.75 325 29.59 ± 5.53 0.405
Cardiovascular Risk Factors
Tobacco <0.001
Newer 658 65.34% 369 54.19% 289 88.65
Current smoker 86 8.54% 75 11.01% 11 3.37%
Recent ex-smoker (< 6 months) 19 1.89% 19 2.79% 0 0.00%
Former smoker (≥ 6 months) 244 24.23% 218 32.01% 26 7.98%
Smokes (yes) 86 8.54% 75 11.01% 11 3.37% <0.001
Alcohol <0.001
No 419 41.61% 182 26.73% 237 72.70%
Light 495 49.16% 408 59.91% 87 26.69%
Moderate 76 7.55% 74 10.87% 2 0.61%
High 17 1.69% 17 2.50% 0 0.00%
Drink alcohol (yes) 588 58.39% 499 73.27% 89 27.30% <0.001
Hypertension 627 62.26% 410 60.21% 217 66.56% 0.051
Diabetes mellitus 0.203
No 818 81.23% 543 79.74% 275 84.36%
Type 1 6 0.60% 5 0.73% 1 0.31%
Type 2 183 18.17% 133 19.53% 50 15.34%
Diabetes mellitus (yes) 189 18.77% 138 20.26% 51 15.64% 0.079
Dyslipidemia 487 48.36% 333 48.90% 154 47.24% 0.622
LA: left atrium; LVEF: left ventricular ejection fraction; HF: heart failure; HTN: arterial hypertension; COPD: chronic obstructive pulmonary
disease; AF: atrial fibrillation.
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3.9. Anticoagulation
Almost 90% of the global patients received anticoagulation–the proportion being
higher in women (94.1% versus 87.6%; p = 0.001). Vitamin K antagonists were the most
widely prescribed drugs (58.8%), followed by dabigatran (34.4%), rivaroxaban (28.2%),
apixaban (23.9%) and edoxaban (14.4%). The mean time in therapeutic range was 54.8%,
with no statistically significant differences between men and women. The use of direct-
acting oral anticoagulants (DOACs) was more common in men (43.8% versus 35.8%, p = 0.2).
Dabigatran was the most widely used drug, while the second most frequently prescribed
drug was rivaroxaban in men and apixaban in women (Table 8).
3.10. EQ-5D and ACTS Questionnaires
The EuroQol-5D (EQ-5D) questionnaire was used to assess health-related quality of
life. This tool comprises five health dimensions (mobility, personal care, daily activities,
pain/discomfort and anxiety/depression), each of which has three levels of severity (no
problems, some problems or moderate problems, and serious problems). Statistically
significant gender differences were recorded (p < 0.001) terms of the EQ-5D (summarizing
score), with higher scores in men (0.85 versus 0.74) (Table 10).
The index ranges from 1 to 0. On the other hand, the mean EQ-5D score was seen
to be higher among the patients subjected to rhythm control than in those in which rate
control was decided, regardless of gender–though both management strategies were more
commonly used in men (Figure 1).
Table 10. EQ-5D questionnaire.
Variables All Men Women p-Value
EQ-5D questionnaire 941 93.45 639 93.83 302 92.64 0.474
Mobility 941 639 302 <0.001
I have no problems
walking 648 68.86% 489 76.53% 159 52.65%
I have some problemswalking 288 30.61% 149 23.32% 139 46.03%
I have to stay in bed 5 0.53% 1 0.16% 4 1.32%
Personal care 941 639 302 <0.001
I have no problems with personal care 862 91.60% 599 93.74% 263 87.09%
I have some problems
washing or dressing 73 7.76% 39 6.1% 34 11.26%
I am unable to wash or dress myself 6 0.64% 1 0.16% 5 1.66%
Daily life activities 941 639 302 <0.001
I have no problems performing
daily life activities 722 76.73% 520 81.38% 202 66.89%
I have some problems
performing daily life activities 202 21.47% 114 17.84% 88 29.14%
I am unable to perform
daily life activities 17 1.81% 5 0.78% 12 3.97%
Pain/discomfort 941 639 302 <0.001
I have no pain or discomfort 652 69.29% 485 75.9% 167 55.3%
I have moderate pain or discomfort 262 27.84% 139 21.75% 123 40.73%
I have much pain or discomfort 27 2.87% 15 2.35% 12 3.97%
Anxiety/depression 941 639 302 <0.001
I am not anxious or depressed 655 69.61% 484 75.74% 171 56.62%
I am moderately anxious or depressed 254 26.99% 137 21.44% 117 38.74%
I am very anxious or depressed 32 3.40% 18 2.82% 14 4.64%
EQ-5D index (summarizing score) * 941 0.82 ± 0.21 639 0.85 ± 0.19 302 0.74 ± 0.22 <0.001
* EQ-5D index (summarizing score): The steps described in the article by Herdman M., Badia X. and Berra S. (2001) were followed to
calculate the index value of any health condition. EuroQol-5D: a simple alternative for assessing health-related quality of life in primary
care. Atención Primaria, 28(6), 425–429.
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benefit) referred to anticoagulation therapy. Men reported greater satisfaction with the
treatment (burden score 53.9 versus 52.3; p < 0.002). However, no gender differences were
observed in terms of the benefit score, negative impact (general burden score), or positive
impact (general benefit score) referred to anticoagulant drug use (Table 11).
Table 11. ACTS scale.
ACTS Questionnaire
Variables All Men Women p-Value
Burden scale 738 53.43 ± 7.95 493 53.98 ± 8.02 245 52.31 ± 7.71 < 0.001
Benefit scale 738 11.34 ± 2.55 493 11.38 ± 2.62 245 11.26 ± 2.42 0.389
General burden scale 738 1.69 ± 1.01 493 1.67 ± 1.02 245 1.74 ± 1 0.224
General benefit scale 738 3.63 ± 1.01 493 3.62 ± 1.04 245 3.65 ± 0.95 0.980
4. Discussion
Our results suggest that once the different characteristics of men and women are
considered, there are no differences between the sexes in the level of anticoagulation or
goals achieved, while differences are observed in the therapeutic strategy of AF that may
have implications for the quality of life of these patients.
In our study, proximately one-third of the patients in our study (32.3%) were women.
This smaller proportion of females is consistent with the data found in the literature, where
lower incidences and prevalences are reported, together with a lesser risk of developing
AF during life in comparison with males [2]. In North America and Europe, the age-
adjusted incidence of AF is 1.5–2 times higher in men than in women, as evidenced by
the Framingham trial [3–5] and the Olmstead County trial in Minnesota [9]. Furthermore,
a disproportionate increase in the incidence of AF has been observed with aging in both
genders [10]. The age-adjusted prevalence was also found to be lower in women (7.4%
versus 10.3% in men) in a retrospective study of Medicare patients in the United States aged
65 years and older. These figures in turn are similar to those reported by a randomized
trial in Sweden in 75-year-old subjects (9.2% in women versus 15% in men) [11].
J. Clin. Med. 2021, 10, 3846 11 of 14
In the last 50 years we have evidenced a rise in both the incidence and prevalence
of AF in the population [1,2], with no significant differences in the growth rates between
males and females. Nevertheless, the absolute number of women with AF is greater than
the number of men, due to the longer life expectancy of the former [12]. In our study, the
women were 6 years older than the men on average (71.6 versus 65.7 years; p < 0.001). This
observation is consistent with the data found in the literature, where in general women
with AF are older than the men [3]. Age appears to be the most important risk factor for
AF, with an up to two-fold increase in incidence for every additional 10 years of age [13].
The results of the BiomarCaRE consortium [12] indicate that on average, women develop
AF a decade later than men. A probable hormone protective effect has been postulated in
this regard, making development of the arrhythmia unlikely before menopause [14].
In concordance with the observations of other studies our women presented a higher
prevalence of HTN and valve disease than the men, and a lower prevalence of coronary
disease [15]. On the other hand, males had a significantly higher alcohol intake than
women, and tended to present a greater association between alcohol consumption and the
risk of developing AF [16].
COPD, strongly associated to smoking, was significantly more frequent in men (46%
of whom were smokers, versus 11% of the women), and was associated to the develop-
ment of AF [17].
From the structural perspective, we know that dilatation of the left atrium is associated
to an increased risk of AF [18]. In this regard, the left atrium was generally smaller in
our women (the mean diameter being 42.7 mm versus 44.5 mm in males), which could
contribute to explain the lesser prevalence of AF among females.
In addition to being associated to an increase in cardiovascular events and mortal-
ity [19], we know that AF has a negative impact upon patient quality of life [20]. In our
study, women reported arrhythmia-related symptoms more often (28.2% of women in class
I versus 36.4% of men), and moreover presented a poorer level of symptoms (EHRA classes
IIb and III). The analysis of the database of the Euro Observational Research Program on
Atrial Fibrillation (EORP-AF) Pilot survey [17], which examined the gender-related differ-
ences among patients with AF in Europe, showed women to be more often symptomatic
than men, with a greater proportion of women in EHRA classes III and IV (p = 0.0012).
Permanent AF was the most frequent presentation of arrhythmia in women, with no
significant differences in the prevalence of paroxysmal AF between the two genders. This
is in contrast to the findings of the EORP-AF trial [17], where the prevalence of paroxysmal
AF was seen to be higher in females (28.5% versus 25.1%), with very similar permanent
AF rates in both groups (17.5% and 17.1%). Likewise, the BEAT-AF [21], a prospective,
multicenter observational study of 1553 patients with AF (mean age 70 ± 11 in women and
67 ± 12 years in men), reported a higher frequency of paroxysmal AF in women (60.6%
versus 53.7%; p = 0.04). In further considering gender-related differences, a multivariate
analysis found the female gender to remain as a potent predictor of symptoms (odds ratio
[OR]: 2.6; 95% confidence interval [95%CI], 2.1–3.4; p < 0.0001), adjusted for variables such
as age or the presence of comorbidities, within a sub-study of the ORBIT AF registry [22].
In our study, women had poorer perceived health as determined by the EQ-5D. This is
consistent with the observations of the BEAT-AF study [21] and EORP-AF trial [17]. In both
genders, perceived health status was better in those patients subjected to a rhythm control
management strategy versus rate control, though the scores were comparatively higher
in men. Other studies have evidenced that if sinus rhythm is achieved and maintained,
similar improvement of quality of life is observed in both genders [23]. In the BATE-AF
trial, the symptoms burden decreased 56% among those patients subjected to rhythm
control, but only 28.4% in the absence of such treatment [21].
Women present symptoms more often than men, though a comparatively lesser
proportion of them are subjected to rhythm control measures compared with men. rate
control is more common, despite the fact that it seems clear that rhythm control strategies
improve quality of life and perceived health status, independently of patient gender [1,23].
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A total of 55.8% of the women in our study were subjected to rhythm control versus
66.6% of the men (p = 0.001), with statistically significant differences in the electrical
cardioversion (ECV) rate, which proved lower in women (27.3% versus 18.4%; p = 0.002).
No gender differences were observed in relation to catheter ablation (16.8% versus 16.2%;
p = 0.8). These observations are similar to those of the EORP-AF trial [17], with ECV rates in
women and men of 18.9% versus 25.5%, respectively (p = 0.0001). On stratifying according
to symptoms, in the presence of typical symptoms, women were less likely to be subjected
to rhythm control strategies (p = 0.002). On the other hand, the women in the BEAT-AF
study [21] had a significantly lower prevalence of interventions (understood as ECV or
ablation) than the men (30.7% versus 38.9%; p = 0.002).
It could be speculated whether this lower use of rhythm control strategy in the
women of our study was due to the clinical profile of the women who developed AF
(age, comorbidities, etc.), the perception of a greater frequency of complications with the
invasive strategy (with the reporting of a risk of complications 1.28 to 2.3 times higher than
in men) [24], lesser efficacy (women have greater atrial fibrosis and a greater presence of
triggers outside the pulmonary veins) [25], or the increased risk of malignant ventricular
arrhythmias associated to the use of class III AADs [26,27]. In our study, men received
AADs more often than women, in clear correlation to the greater use of rhythm control
strategies among the former. In the patients of the EORP-AF study [17], the differences
were less manifest (39.7% versus 36.6%) and failed to reach statistical significance.
Although we recorded no statistically significant differences in the prevalence of
thromboembolic events between men and women, the latter presented greater risk, since
the CHA2DS2-VASc risk score, with a mean value of 3, was one point higher than in men
(p < 0.001). The HAS-BLED bleeding risk score was also higher in women (0.8 versus
0.6; p < 0.001). In this regard, women more often received anticoagulation therapy (94.1%
versus 87.6%; p = 0.001), in abidance with the clinical practice guides, which describe
the female gender as an independent predictor of stroke risk in the presence of one or
more risk factors for thromboembolism [7]. The results of the EORP-AF study showed
oral anticoagulation to be used in a similar manner in both genders (81.5% versus 79.8%;
p = 0.36), with VKAs being the most commonly prescribed drugs (72.7%). On considering
a CHA2DS2-VASc risk score of ≥2, the differences were found to be significant in favor
of women (94.7% versus 74.6%; p < 0.0001). Vitamin K antagonists were also the most
frequently used drugs in the patients of our study (58.8%). The mean time in therapeutic
range was 54.8%, with no statistically significant differences between men and women.
The use of DOACs was more frequent in men (43.8% versus 35.8%), though statistical
significance was not reached (p = 0.2).
5. Conclusions
The analysis of the patients in the REGUEIFA study revealed differences between
men and women diagnosed with AF in Galicia. Women were older and presented greater
comorbidity compared with men. Due to the comparatively greater thromboembolic risk in
women, the latter received anticoagulation treatment more often than men, in concordance
with the clinical practice guides, with no differences regarding the time in therapeutic
range between the two genders. In general, rhythm control measures were less frequently
prescribed in women than in men, despite the fact that the former had poorer perceived
quality of life and were more often symptomatic. Knowing that rhythm control improves
the quality of life of patients of either gender, we should seek to improve the treatment and
clinical management of women with AF.
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